Welcome to our dedicated page for MANNKIND SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MANNKIND's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MANNKIND's regulatory disclosures and financial reporting.
Dominic Marasco, President of the Endocrine Business Unit at Mannkind, received a significant performance-based equity award on June 23, 2025. The insider was granted 1,000,000 performance restricted stock units (PRSUs) that represent the right to receive an equivalent number of common stock shares.
Key terms of the PRSU grant:
- Vesting date set for March 15, 2028
- Final payout ranges from 0% to 200% of target shares based on net sales performance
- Target amount is 1,000,000 shares, meaning maximum potential payout is 2,000,000 shares
- Exercise price of $0, making this a full-value award
This significant equity grant aligns the executive's interests with long-term company performance, specifically tied to net sales targets over an approximately 3-year performance period.